• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Brief, Sporadic Physical Activity Like Climbing Stairs Reduce Mortality Risk?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The benefits of physical activity are well known, but impact of vigorous intermittent lifestyle physical activity (VILPA), such as climbing stairs or walking quickly for a bus, has not been well studied
  • Stamatakis et al. (Nature Medicine, 2022) examined the association of VILPA with all-cause, cardiovascular disease (CVD) and cancer mortality in the UK  

METHODS:

  • Secondary analysis of prospective cohort study
    • UK Biobank
  • Population
    • Non-exercisers 40 to 69 years who wore a wrist-worn accelerometer for 7 days
  • Exposure
    • VILPA frequency and duration
  • Primary outcome
    • All-cause, CVD and cancer mortality risk

RESULTS:

  • 25,241 nonexercisers
    • Mean age 61.8 years | 56% women
    • Mean follow-up 6.9 years
    • Deaths: 852

VILPA was inversely associated with all three primary outcomes in a near-linear fashion

  • Participants who engaged in 1-minute long VILPA at the median VILPA frequency (3 length-standardized bouts per day lasting 1 or 2 minutes each) experienced a reduction in mortality risk vs no VILPA
    • All-cause mortality: Hazard ratio (HR) 0.61 (95% CI, 0.50 to 0.74)
    • Cancer mortality: HR 0.60 (95% CI, 0.46 to 0.78)
    • CVD mortality: HR 0.51 (95% CI, 0.35 to 0.74)
  • VILPA at the sample median duration of 4.4 minutes per day was also associated with a reduction in mortality risk
    • All-cause mortality: HR 0.73 (95% CI, 0.63 to 0.85)
    • Cancer mortality: HR 0.70 (95% CI, 0.59 to 0.84)
    • CVD mortality: HR 0.66 (95% CI, 0.50 to 0.88)
  • Results were similar when comparing vigorous physical activity in participants who exercised

CONCLUSION:

  • Brief, sporadic bouts of vigorous, non-exercise physical activity are associated with reduced mortality
  • The authors state

Moreover, the sample median VILPA duration of 4.4 min per day was associated with a 26%–30% reduction in all-cause and cancer mortality risk and a 32%–34% reduction in CVD mortality risk

Our approach shows that wearable devices combined with machine learning-based methods and self-reported information can reveal physical activity “micro-patterns” as targets to prevent premature mortality, CVD and cancer in populations not willing and/or not able to engage in structured exercise during leisure time

Learn More – Primary Sources:

Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

More From the PURE Study: Does Type of Exercise Matter When it Comes to Decreasing Mortality and CVD?  
Long Term Data on Mortality Reduction and Physical Activity Guidelines
How Many Deaths Could Be Prevented Annually by Increasing Daily Physical Activity by 10 Minutes?
Does Vigorous Physical Activity Further Reduce Risk for Cardiovascular Disease?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site